CClinicalTrials.gg
CompletedNCT05876559Updated Apr 8, 2025

Joyuus - A Web-based Tool for Postpartum Care Self-care for Underserved Women

An interventional study of Joyuus Self-care Mobile App and Standard Care in Maternal Health, sponsored by Joyuus, LLC. Completed at 1 site in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Joyuus, LLC · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

The goal of this RCT is to evaluate the effectiveness of Joyuus on improving maternal functioning with postpartum moms. The main questions it aims to answer are:

  • The primary hypothesis is that participants of the Joyuus program will demonstrate improved functional status compared to the control arm participants at 3-month follow-up.
  • The secondary hypotheses are that participants using the Joyuus tool will demonstrate improvement in depression, anxiety, resilience, social support, and knowledge compared to the control arm at 6- and 12-weeks follow-up.
Read the detailed description

In the United States, the postpartum period is a critical time for both maternal and child health; the US maternal mortality rate is the highest among other developed, high-income countries. More than half of all maternal deaths occur postpartum, from one day to one year after birth. There are vast racial and ethnic disparities in maternal mortality and severe morbidity, disproportionately experienced by Black and Latina mothers and other BIPOC women. Black women are 3-4 times more likely to experience maternal mortality than white women10, and Hispanic women are twice as likely to experience severe maternal outcomes compared with non-Hispanic white women. The American College of Obstetricians and Gynecologists recognized the deficiencies in postpartum care and coined the term the 'fourth trimester' to mark the time following birth through the first 3-months postpartum. They recently updated recommendations to address these challenges. The Biden Build Back Better Act also prioritized this issue. Joyuus is a web-based self-care mobile tool addressing the 12 months postpartum, to reduce the risks of avoidable morbidity and mortality for underserved women. The tool addresses physical, mental, real world, cultural, and knowledge barriers which impact quality postpartum care. Joyuus provides information, resources, expert perspectives, peer communications and red flags presented in a variety of formats to help women identify how to adopt healthy self-care habits. Importantly, it also identifies when self-care leads to seeking provider care. Pregnant women often turn to the internet to find information about their health and their developing baby's health. Yet, studies find that mothers are not finding sufficient resources to match their postpartum needs. The Phase I grant demonstrated in a sample of Black women that this audience is highly engaged across the income and education spectrum and prefers mobile access and text-based communication. In Phase II work will continue to include lived experiences of women most at risk for negative postpartum outcomes as part of the complete tool. The first step will be to conduct a needs assessment to understand informational, cultural and language wants and needs in the Latina population. The broader randomized trial will invite a diverse population of BIPOC and white women. The Phase II scope aims to complete three major tasks:

AIM 1: Expand feasibility activities to address Latina population. Explore self-care (and seeking care) needs for the postpartum Latina community and integrate with the Phase I focus group findings.

AIM 2: Build complete tool. The investigators will complete the development of a fully interactive Joyuus web based mobile tool in English and Spanish.

AIM 3: Test in randomized controlled trial. The investigators will test the effectiveness of Joyuus with a diverse national sample of postpartum women, considering the impact on maternal function, depression, anxiety, resilience, knowledge, and social support.

02

Conditions studied

  • Maternal Health
03

In context

Lead sponsor

This is the only study on the registry with Joyuus, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Must be age 18 or older
  • Must be between 0-6 months postpartum
  • Must have a smartphone with internet access and are willing to use this device to participate in all study activities; and
  • Must be able to speak, read, and write in English

Exclusion criteria

Exclusion Criteria:

  • Medical/health issues which would impact participants' health or ability to participate
  • Did not have a live birth
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    active intervention group

    Participants will receive immediate access to Joyuus selfcare mobile app

    Other: Joyuus Self-care Mobile App

  • Active comparator
    standard care control group

    Participants will receive standard care, and will not have access to Joyuus selfcare mobile app until study completion.

    Other: Standard Care

Interventions

  • OtherJoyuus Self-care Mobile App

    Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.

  • OtherStandard Care

    Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.

06

What researchers measure

Primary outcomes

  1. Barkin Index of Maternal Functioning (BIMF)

    The BIMF is a 20-item self-report measure designed to assess overall functioning in the context of new motherhood. Functional domains include social support, management, mother-child interaction, infant care, self-care, adjustment, and psychological well-being (of the mother). The BIMF demonstrates strong internal consistency. with Cronbach's alpha for the full 20-item scale between .83-.87 indicating strong inter-item agreement. A total score is generated from summing the 20 items (after the reverse-coding of items 16 and 18) and ranges from 0 to 120. Higher total scores are associated with greater levels of functioning.

    Time frame: Change between baseline and 12 months

Secondary outcomes

  1. Edinburgh Postnatal Depression Scale (EPDS)

    (EPDS), a reliable, valid, and widely used scale that measures the presence and intensity of depressive symptoms. The scale has high internal consistency, test-retest reliability, and construct validity. Each answer is given a score of 0 to 3. The total scores are calculated with a maximum score of 30. Lower scores indicate lower presence or intensity.

    Time frame: Change between baseline and 12 months

  2. State-Trait Anxiety Inventory (STAI)

    The STAI has 20 items for assessing trait anxiety and 20 for state anxiety. Considerable evidence attests to the reliability and validity of the scale. Each type of anxiety has its own scale of 20 different questions that are scored. Scores range from 20 to 80, with higher scores correlating with greater anxiety.

    Time frame: Change between baseline and 12 months

  3. Connor-Davidson Resilience Scale (CDRS)

    The CDRS is a 25-item scale covering 17 resilience domains and used across languages, racial/ethnic, and cultural groups. It has been shown to have strong psychometric properties and has validated short forms. CDRS uses a scale of 0-4 with 0 being not true at all, to 4 being true nearly all the time.

    Time frame: Change between baseline and 12 months

Other outcomes

  1. COVID-19 and Mental Health Impacts Scale

    While not a formal endpoint, a descriptive analysis of this measure will be conducted. The COVID-19 Community Response Survey, Mental Health Impact Module is a 13-item questionnaire that was developed to better understand people's experiences about how their lives have changed as a result of COVID-19. Question 1 is a four point scale from Not at all, to 5-7 days. More days indicates increased impact. Questions 2-13 are scored on a 5 point scale from Strongly Disagree to Strongly Agree, with stronger agreement indicating increased impact.

    Time frame: Change between baseline and 12 months

  2. Maternal Health Knowledge

    Knowledge will be assessed by a brief study-specific multiple-choice instrument, to be developed as part of this modest trial, and designed to test understanding of evidence-based concepts presented in the Joyuus tool. While not a formal endpoint, a descriptive analysis of this measure will be conducted. Questions will be scored on a 5 point scale from Strongly Disagree to Strongly Agree, with stronger agreement indicating increased knowledge.

    Time frame: Change between baseline and 12 months

07

Study locations

1 site
  • Lisa Marceau
    Westerly, Rhode Island 02817, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876559
Lead sponsor
Joyuus, LLC
Collaborators
National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Jan 15, 2024
Primary completion
Oct 15, 2024
Completion
Oct 15, 2024
Last update
Apr 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion